Intelligent Bio Solutions Inc. Stock

Equities

INBS

US36151G6008

Biotechnology & Medical Research

End-of-day quote Nasdaq 18:00:00 2024-04-29 EDT 5-day change 1st Jan Change
2.69 USD -3.93% Intraday chart for Intelligent Bio Solutions Inc. -3.24% -33.66%
Sales 2024 * 4.18M 5.76M Sales 2025 * 9.43M 12.98M Capitalization 7.65M 10.53M
Net income 2024 * -8M -11.02M Net income 2025 * -6M -8.26M EV / Sales 2024 * 1.83 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 0.81 x
P/E ratio 2024 *
-0.73 x
P/E ratio 2025 *
-0.78 x
Employees 51
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.4%
More Fundamentals * Assessed data
Dynamic Chart
1 day-3.93%
1 week-3.24%
1 month-36.26%
3 months+7.60%
6 months+3.64%
Current year-33.66%
More quotes
1 week
2.45
Extreme 2.45
2.90
1 month
2.45
Extreme 2.45
4.11
Current year
2.28
Extreme 2.28
11.70
1 year
2.28
Extreme 2.28
49.20
3 years
2.28
Extreme 2.28
1 226.40
5 years
2.28
Extreme 2.28
3 417.58
10 years
2.28
Extreme 2.28
3 417.58
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 17-08-31
Chairman 67 20-06-30
Director of Finance/CFO 63 19-03-31
Members of the board TitleAgeSince
Director/Board Member 86 20-07-31
Chief Executive Officer 56 17-08-31
Director/Board Member 54 18-03-31
More insiders
Date Price Change Volume
24-04-30 2.69 -3.93% 30,316
24-04-29 2.8 +4.09% 40,400
24-04-26 2.69 +8.91% 40,699
24-04-25 2.47 -3.89% 52,608
24-04-24 2.57 -7.55% 51,711

End-of-day quote Nasdaq, April 29, 2024

More quotes
Intelligent Bio Solutions Inc. is a life sciences company. The Company is engaged in developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It operates through two segments, namely Commercially available Intelligent Fingerprinting Products (IFPG) and Development Stage Saliva Glucose Biosensor Platform (SGBP). Its product portfolio includes a portable drug screening system that works by analyzing fingerprint sweat using a one-time cartridge and portable handheld reader and also includes a development stage range of biosensor- based Point of Care diagnostic tests (POCT) that are developed in the modalities of clinical chemistry, immunology, tumor markers, allergens, and endocrinology. Its product candidate is the Saliva Glucose Biosensor (SGB), a POCT expected to substitute the finger pricking invasive blood glucose monitoring for diabetic patients. Its Biosensor Platform helps to detect multiple biological analytes.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.69 USD
Average target price
42 USD
Spread / Average Target
+1,461.34%
Consensus